Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2022-06-16 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
第三届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the eighth meeting of the third board of directors of Zhejiang Tailin Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and next steps such as submitting proposals to the upcoming extraordinary general meeting. The content focuses on board meeting decisions and governance matters rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, nor a call transcript or earnings release. The document fits the category of Board/Management Information (MANG) as it announces board meeting resolutions and management decisions.
2022-06-16 Chinese
2021年浙江泰林生物技术股份有限公司创业板向不特定对象发行可转换公司债券2022年跟踪评级报告
Audit Report / Information Classification · 95% confidence The document is a detailed credit rating report for Zhejiang Tailin Biotechnology Co., Ltd. regarding its convertible bonds issued in 2021, with a follow-up rating in 2022. It includes extensive financial data, credit ratings, company background, industry environment, policy context, and operational analysis. The content is typical of a credit rating or audit-related report rather than a general annual or quarterly report. It is not an earnings release, call transcript, or management report. The document is not a brief announcement or a proxy statement. It is a standalone credit rating report with detailed financial and operational analysis, which fits the category of an Audit Report / Information (AR) as it relates to credit rating and financial assessment but is not a full annual report (10-K) or interim report (IR). Therefore, the most appropriate classification is AR (Audit Report / Information).
2022-06-16 Chinese
关于取得专利证书及软件著作权证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of patent certificates and software copyright certificates by the company and its subsidiaries. It details the specific patents and software copyrights obtained, their types, application numbers, and dates. There is no financial data, no mention of financial results, no regulatory certifications, or meeting-related information. The document is an official announcement of intellectual property achievements, which does not fit into financial reports, management changes, or other categories related to financial performance or governance. It is a regulatory announcement informing the market about new patents and copyrights, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-06-10 Chinese
关于全资子公司变更注册资本并完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a capital increase in a wholly-owned subsidiary and the completion of related business registration changes. It details the change in registered capital and provides updated business license information. The document is short (1091 characters) and focuses on a specific capital change event rather than a full financial report or detailed financial data. It does not contain financial statements or comprehensive financial analysis. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2022-06-09 Chinese
关于泰林转债转股价格调整的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the adjustment of the conversion price of its convertible bonds (convertible company bonds). It references regulatory approval from the China Securities Regulatory Commission and details the adjustment formula and the effective date of the new conversion price. The document is a formal notice about a change in the terms of convertible bonds, specifically the conversion price adjustment, which is a capital structure change. It does not contain financial statements or comprehensive financial data, nor is it a report or presentation. It is an announcement about a capital/financing update related to convertible bonds. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is short and focused on this specific update, not a report publication or regulatory filing. Confidence is high due to clear content and context.
2022-05-10 Chinese
2021年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the implementation of the 2021 annual equity distribution plan (dividends and stock bonus) approved at the 2021 annual general meeting held on May 9, 2022. It details the dividend amount, stock bonus ratio, record date, ex-dividend date, and other procedural information related to the equity distribution. The document is relatively short (2898 characters) and focuses on the announcement of the dividend and stock bonus distribution rather than presenting a full annual report or financial statements. It does not contain comprehensive financial data or management discussion but is a formal notice of the dividend and stock bonus distribution to shareholders. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-05-10 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.